Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Key Highlights
- ➤FDA aligns on REC-4881 Phase 3 design for familial adenomatous polyposis
- ➤Primary endpoint includes excision of adenomas ≥10 mm across the GI tract
- ➤Approximately 200 post-colectomy adults expected to enroll in the trial
- ➤Phase 3 trial remains on track to begin in the second half of 2027
- ➤TUPELO data showed 47% median polyp-burden reduction after 12 weeks at 4 mg
Expert Statements
Evelien Dekker, Head of Expert Clinic for Familial and Hereditary Polyposis and Colorectal Cancer, and Professor of Gastrointestinal Oncology, Amsterdam University Medical Center
“Adenomas 10 millimeters and larger are associated with increased cancer risk and are nowadays routinely removed in patients with FAP. However, removal carries risks of bleeding and perforation, alongside the burden of repeated procedures and intensive surveillance”
Evelien Dekker, Head of Expert Clinic for Familial and Hereditary Polyposis and Colorectal Cancer, and Professor of Gastrointestinal Oncology, Amsterdam University Medical Center
“There is a substantial unmet need for a therapy that could prevent adenomas from reaching this size or developing in cancer. Reducing the need for these interventions could provide a meaningful benefit to patients.”
Robert Hüneburg, MD, Senior Gastroenterologist and Head of the Hereditary Tumor Clinic, National Center for Hereditary Tumor Syndromes, Department of Internal Medicine I, University Hospital Bonn, Germany
“Patients with familial adenomatous polyposis face a lifelong burden of endoscopic surveillance, repeated interventions, and frequently major surgery. A medical therapy that could safely and durably prevent the progression of adenomas, reduce the need for endoscopic interventions, and potentially delay or avoid major surgery would represent a significant advance in the management of FAP.”
Najat Khan, Ph.D., President and Chief Executive Officer of Recursion
“For people living with FAP, colectomy does not end the disease. Patients continue to face decades of lifelong surveillance, repeated polyp removal and, for some, further major surgery”
Najat Khan, Ph.D., President and Chief Executive Officer of Recursion
“Our Phase 2 TUPELO results showed substantial and rapid reductions in polyp burden across the GI tract, including larger, higher-risk polyps, supporting our advancement toward a registrational trial. Securing FDA alignment on a novel component of our primary endpoint - counting the removal of adenomas 10 mm or larger across both the upper and lower GI tract as events - is a key milestone, reflecting an important and clinically meaningful intervention in FAP care. We appreciate the FDA’s constructive engagement and look forward to starting the trial in the second half of 2027, with the goal of bringing a much-needed treatment option to people living with FAP.”
* REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion’s AI foundation models. * Achieved a key regulatory milestone with FDA alignment on including excision of adenomas ≥10 mm throughout the GI as a novel and clinically meaningful event in the composite event-free survival primary endpoint. Adenomas of this size are associated with an increased risk of high-grade dysplasia, and cancer. * Modified Spigelman stage progression and total polyp burden will be included among secondary endpoints. * The trial is expected to enroll approximately 200 adults with FAP following colectomy or proctocolectomy and is on track to begin in the second half of 2027.
Salt Lake City, UT, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that it has aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for the treatment of familial adenomatous polyposis (FAP). The alignment includes a composite event-free survival primary endpoint with a novel, clinically meaningful component: excision of an adenoma 10 mm or larger in either the upper or lower gastrointestinal (GI) tract. The trial is on track to begin in the second half of 2027.
Get started
Create a free account to read the full story.
